The oral combination of xanomeline and trospium effectively treats schizophrenia without unwanted side effects.
Neuroscience
Posted inClinical Trials, Neuroscience
Treating Parkinson’s disease with diabetes and obesity drugs
GLP1R agonists like lixisenatide, exenatide, or semaglutide limit the progression of motor dysfunction in Parkinson’s disease.
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory
Duvyzat: Givinostat for Duchenne Muscular Dystrophy Treatment
Oral givinostat delays the progression of DMD.
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory
Relyvrio/Albrioza: New Drug for Amyotrophic Lateral Sclerosis Treatment
Amylyx Pharmaceuticals proposed mixture of sodium phenylbutyrate and tauroursodeoxycholic acid for ALS treatment.
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory
Skysona: Gene Therapy for Cerebral Adrenoleukodystrophy
A single dose of the elivaldogene autotemcel will cure a deadly disease.
Posted inNeuroscience, New Drugs, Regulatory
Auvelity: New Antidepressant for Most Severe Depression
Dextromethorphan and bupropion: A powerful drug combination that will help with depression that cannot be treated with standard antidepressants.
Posted inClinical Trials, Neuroscience, Rare/Orphan Diseases
Qalsody: New Drug for Amyotrophic Lateral Sclerosis with SOD1 Mutation
Tofersen and the mixed results of treatment for the deadly neurodegenerative disease.